paul b

Amylin Pharmaceuticals: Not Worth $6.22 Billion

Relentlessly negative, and Byetta and Januvia are not very similar at all.

Nonetheless, Amylin has been badly mismanaged. A tremendous market opportunity for Byetta was squandered. Marketing has been beyond inept. Yet while income has been thus hampered, growth plans have good ahead full tilt. Secondaries and convertibles abound, eclipsed only by the lavish perennial incentive options.

In short, the intermediate term has been mortgaged in hopes of future greatness. That could still come about, but management demonstrated a bad inability to sell the wonderful drugs they already have. The only thing I can say good about the co at this juncture is the R&D, top-class in the metabolic space. Hopefully the science will prevail, but it will take time.